Clinical Trial Detail

NCT ID NCT01326871
Title A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Altor Bioscience Corporation, National Cancer Institute (NCI)
Indications

urethra transitional cell carcinoma

invasive bladder transitional cell carcinoma

infiltrating ureter transitional cell carcinoma

infiltrating renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

ALT-801

Age Groups: adult

No variant requirements are available.